Drug Trial Radar · NCT05032040
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Jul 21, 2022
Primary completion
Oct 15, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Xencor, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Sep 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Conditions
- Ovarian Cancer
- Clear Cell Carcinoma
- Endometrial Cancer
- Cervical Carcinoma
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
vudalimabBiological
Monoclonal bispecific antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohortsTime frame: 12 weeks
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC - NAHOA
Prescott, Arizona
UCSD Moores Cancer Center
La Jolla, California
Valkyrie Clinical Trials
Los Angeles, California
UCLA Medical Center
Los Angeles, California
Kaiser Permanente Medical Group
Riverside, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Rocky Mountain Cancer Centers
Aurora, Colorado
Medical Oncology Hematology Consultants, PA
Newark, Delaware
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Karmanos Cancer Institute
Detroit, Michigan
Comprehensive Cancer Centers of Nevada-Southern Hills
Las Vegas, Nevada
NYU Langone Health
New York, New York
Columbia University Medical Center
New York, New York
University of Pennsylvania Health System
Philadelphia, Pennsylvania
Texas Oncology - Central South
Austin, Texas
Virginia Oncology Associates
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.